AT Uro Congress
May 22-24, 2025
Vienna, Austria
News and Events
Subscribe to our press distribution list to receive the latest news about AMW.
Upcoming
Events
EuroPLX
June 2-3, 2025
Lisbon, Portugal
CPHI South East Asia 2025
July 16-18, 2025
Kuala Lumpur, Malaysia
https://www.cphi.com/sea/en/home.html
CPHI 2025
October 28-30, 2025
Frankfurt, Germany
https://www.cphi.com/europe/en/home.html
BIO-Europe 2025
November 3-5, 2025
Vienna, Austria
https://informaconnect.com/bioeurope/
Past
Events
Archive
Pharmapack
January 24-25, 2024 Paris, France https://www.pharmapackeurope.com/
read morePharmasynergy
February 08-09, 2024
London, UK
euroPLX84
February 26-27, 2024 Lisbon, Portugal
read moreBIO-Europe Spring
March 18-20, 2024
Barcelona, Spain
https://informaconnect.com/bioeurope-spring/
4th Wet AMD & Diabetic Eye Disease Drug Development
March 19-21, 2024
Boston, MA
https://wet-amd-drug-development.com/
BIO International Convention
June 03-06, 2024
San Diego, California
https://www.bio.org/events/bio-international-convention
CPHI South East Asia
July 10-12, 2024 Bangkok, Thailand https://www.cphi.com/sea/en/home.html
read moreCPHI 2024
October 08-10, 2024 Milan, Italy https://www.cphi.com/europe/en/home.html
read morePODD – Partnership Opportunities in Drug Delivery
October 28-29, 2024 Boston, USA https://poddconference.com
read moreBIO-Europe
November 04-06, 2024 Stockholm, Sweden https://informaconnect.com/bioeurope/
read morePharmaSynergyRx 2025
February 27-28, 2025
London, UK
https://pharma-synergy-conference.com/pharmasynergy-2025/
BIO-Europe Spring
March 17-19, 2025
Milan, Italy
https://informaconnect.com/bioeurope-spring/
DCAT Week 2025
March 17-20, 2025
New York City, USA
https://dcatweek.org/
Latest
News
For the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.
The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.
read moreBfArM approvals from DCP procedure for Rivastigmin patches granted for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic
On 28 August 2015, the BfArM granted approvals from DCP procedures for rivastigmin patches at doses 4.6 mg/24 h and 9.5 mg/24 h for Germany, Austria, Romania, Sweden, Slovakia and the Czech Republic.
read moreSuccessful financing round for pharmaceutical company AMW
AMW GmbH (Arzneimittelwerk Warngau) has received follow-on financing to advance the development and commercialization process for its drug delivery systems. Together with BayBG Bayerische Beteiligungsgesellschaft, UnternehmerTUM-Fonds and IBG Beteiligungsgesellschaft, the existing investors are putting in a total of up to seven million euros. The funds will be used for the marketing of the existing product portfolio and the development of a new technology for the controlled release of pharmaceuticals. AMW GmbH produces active ingredient implants as well as transdermal systems in the fast-growing fields of oncology, pain therapy and neurology.
read moreAMW GmbH announces that another round of financing has been concluded with the existing shareholders.
AMW GmbH announces that another round of financing has been concluded with the existing shareholders. The funds are used to strengthen further growth and the development of innovative products. Dr. Wilfried Fischer, managing director of AMW GmbH, thanks for the trust of the shareholders in the performance of the company.
read moreIn January 2014, AMW GmbH was able to conclude a semi-exclusive license and supply contract for its biodegradable goserelin implants with a multinational pharmaceutical company.
The contract applies to Southeast Asia, including China, Eastern Europe, Russia and some Western European countries. The agreements contain down payment payments of up to € 10 million, license payments in the double-digit percentage range, and an exclusive delivery agreement for AMW. The partner company will carry out further clinical developments for the contract area.
read more